Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125530821 | 12553082 | 1 | I | 20160708 | 20160713 | 20160713 | EXP | JP-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00315 | SCIEGEN | 78.00 | YR | F | Y | 0.00000 | 20160713 | PH | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125530821 | 12553082 | 1 | PS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Unknown | 75 MG/DAY | U | 204165 | 75 | MG | TABLET | ||||||
| 125530821 | 12553082 | 2 | I | PACLITAXEL. | PACLITAXEL | 1 | Unknown | 60 MG PER WEEK | U | 0 | 60 | MG | |||||||
| 125530821 | 12553082 | 3 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | 40 MG/M2 WEEKLY 6 COURSES | U | U | 0 | 40 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125530821 | 12553082 | 1 | Myocardial infarction |
| 125530821 | 12553082 | 2 | Lung squamous cell carcinoma stage II |
| 125530821 | 12553082 | 3 | Lung squamous cell carcinoma stage II |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125530821 | 12553082 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125530821 | 12553082 | Drug interaction | |
| 125530821 | 12553082 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |